The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Fatima A. Rangwala
Honoraria - Roche/Genentech (I)
Johanna C. Bendell
No relevant relationships to disclose
Mark Kozloff
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Christy Arrowood
No relevant relationships to disclose
Jennifer Meadows
No relevant relationships to disclose
Sandra Ellen Tourt-Uhlig
No relevant relationships to disclose
Jennifer Murphy
No relevant relationships to disclose
Kellen Meadows
No relevant relationships to disclose
Michael Morse
Consultant or Advisory Role - Novartis; Roche/Genentech
Honoraria - Novartis; Roche/Genentech
Research Funding - Novartis
Hope Elizabeth Uronis
Research Funding - Roche/Genentech
Shiaowen David Hsu
No relevant relationships to disclose
Yousuf Zafar
Honoraria - Roche/Genentech
Herbert Hurwitz
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Novartis; Roche/Genentech